NOVOPARYN
Enoxaparin is a low molecular weight heparin (LMWH) with an average molecular weight of approximately 4500 daltons. Its antithrombotic and anticoagulant activities are not directly proportional to those of standard heparin.
Instructions Normative documentsComposition
Active ingredient: enoxaparin sodium;
1 ml of solution contains enoxaparin sodium with anti-Xa activity of 10000 IU, equivalent to enoxaparin sodium 100 mg;
2000 IU anti-Xa / 0.2 ml, equivalent to enoxaparin sodium 20 mg;
4000 IU anti-Xa / 0.4 ml, equivalent to enoxaparin sodium 40 mg;
6000 IU anti-Xa / 0.6 ml, equivalent to enoxaparin sodium 60 mg;
8000 IU anti-Xa / 0.8 ml, equivalent to enoxaparin sodium 80 mg;
10000 IU anti-Xa / 1.0 ml, equivalent to enoxaparin sodium 100 mg;
Excipient: water for injection.
Dosage form
Solution for injection.
Main physicochemical properties: colorless or light yellow clear solution.
Pharmacological group
Antithrombotic agents. Heparin group. Enoxaparin.
ATC code: B01A B05.
Indications
The drug is indicated for use in adults for:
Prophylaxis of venous thromboembolic complications in surgical patients at moderate and high risk, especially in patients undergoing orthopedic or general surgical procedures, including surgery for oncological conditions.
Prophylaxis of venous thromboembolic complications in medical patients with acute illnesses (such as acute heart failure, respiratory failure, severe infections, or rheumatic diseases) and reduced mobility, who are at increased risk of venous thromboembolism.
Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), except in cases of PE where thrombolytic therapy or surgical intervention may be necessary.
Prophylaxis against thrombus formation during extracorporeal circulation in hemodialysis.
In the context of acute coronary syndrome:
For the treatment of unstable angina and non-ST segment elevation myocardial infarction (NSTEMI), in combination with oral aspirin.
For the treatment of ST segment elevation myocardial infarction (STEMI), including in patients planned for medical management or subsequent percutaneous coronary intervention (PCI).
SIDE EFFECTS
Contraindications
Enoxaparin sodium is contraindicated in patients with the following conditions:
Increased sensitivity to enoxaparin sodium, heparin, or its derivatives, including other low molecular weight heparins.
History of immune-mediated heparin-induced thrombocytopenia (HIT) within the past 100 days with circulating antibodies (see also “Special precautions for use” section).
Active clinically significant bleeding and conditions at high risk of bleeding, including recent hemorrhagic stroke, peptic ulcer disease, presence of malignant neoplasms at high risk of bleeding, recent surgery on the brain, spinal cord, or eyes, known or suspected varicose veins of the esophagus, arteriovenous malformations, or serious developmental abnormalities of intraspinal or intracerebral vessels.
Spinal or epidural anesthesia or locoregional anesthesia if enoxaparin sodium has been used for treatment within the previous 24 hours (see “Special precautions for use” section).